DEBIO 0513

Drug Profile

DEBIO 0513

Alternative Names: PTR-262; PTR-262-MG

Latest Information Update: 12 Aug 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DeveloGen
  • Class
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myasthenia gravis

Highest Development Phases

  • No development reported Myasthenia gravis

Most Recent Events

  • 25 Sep 2006 DEBIO 0513 has received Orphan Drug Status in Europe for the treatment of Myasthenia gravis
  • 18 Aug 2005 DEBIO 0513 has been licensed to Debiopharm worldwide for the treatment of Myasthenia gravis
  • 14 Jun 2004 Peptor has been acquired by, and merged into, DeveloGen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top